PRISM MarketView Presents Exclusive Interview with Coya Therapeutics CEO Arun Swaminathan on Targeting Neurodegenerative Diseases with Treg Therapies
FDA IND Clearance: Coya Therapeutics received FDA acceptance for its Investigational New Drug (IND) application for COYA 302, allowing the start of a Phase 2 clinical trial for ALS.
Strategic Partnerships: The company has formed partnerships, notably with Dr. Reddy's Laboratories, to enhance manufacturing, regulatory support, and commercialization efforts.
Pipeline Expansion: Coya plans to file an IND for frontotemporal dementia by late 2025 and is advancing its COYA 303 program, which combines low-dose IL-2 with GLP-1 agonists.
Upcoming Milestones: Key milestones for 2025 include the initiation of the ALS trial, data readouts for frontotemporal dementia, and new preclinical results across various programs.
Trade with 70% Backtested Accuracy
Analyst Views on COYA
About COYA
About the author
Coya Therapeutics Secures $11.1 Million in Private Placement
- Funding Size: Coya Therapeutics announced the sale of approximately 2.52 million shares at $4.40 per share, raising about $11.1 million, which will provide essential capital to accelerate the commercial readiness of its COYA 302 program.
- Investor Background: In this financing round, Dr. Reddy’s Laboratories invested $10 million through a subsidiary, while the company's largest institutional shareholder, Greenlight Capital, contributed $1.1 million, reflecting strong market confidence and support for Coya.
- Use of Proceeds: Coya plans to utilize the funds raised to expedite technology transfer and scale-up manufacturing for low-dose IL-2, thereby enhancing its competitive position in the market as it prepares for the commercialization of COYA 302.
- Transaction Timeline: The private placement is expected to close on or about January 30, 2026, subject to customary conditions, which ensures future liquidity and project advancement for the company.
Coya Therapeutics Secures $11.1 Million in Private Placement
- Funding Amount: Coya Therapeutics has secured approximately $11.1 million through a private placement of 2,522,727 shares at $4.40 each, reflecting strong market confidence in its biologics development.
- Key Investors: The primary investors include Dr. Reddy’s Laboratories, contributing $10 million, and Greenlight Capital with $1.1 million, indicating a positive outlook from institutional investors regarding Coya's future prospects.
- Use of Proceeds: The company intends to utilize the proceeds to accelerate technology transfer and scale-up manufacturing for low-dose IL-2, supporting the commercial readiness of COYA 302, thereby enhancing its competitive position in the neurodegenerative disease market.
- Compliance Commitment: Coya has committed to filing a registration statement with the SEC within 45 days post-closing, ensuring the legal resale of the securities, which will bolster investor confidence and facilitate future capital operations.
Coya Therapeutics Receives FDA IND Approval for COYA 302 to Treat Frontotemporal Dementia
- FDA Approval: Coya Therapeutics announced that its IND for COYA 302 to treat frontotemporal dementia has been accepted by the FDA, marking a significant advancement in the treatment of neurodegenerative diseases and aiming to address the urgent medical needs of approximately 60,000 patients.
- Clinical Need: Frontotemporal dementia is the most common form of dementia in individuals under 65, with an average onset age of 58 and a survival time of only 7.5 years, making Coya's new therapy potentially transformative in improving patient quality of life and slowing disease progression.
- Scientific Rationale: COYA 302 employs a dual immunomodulatory mechanism designed to enhance the anti-inflammatory function of regulatory T cells, which Coya believes will provide a new treatment option for frontotemporal dementia patients, filling a significant gap in the current market with no effective therapies available.
- Clinical Trial Plans: Coya expects to announce topline results from an open-label study evaluating low-dose IL-2 and CTLA4-Ig in patients with mild-to-moderate frontotemporal dementia in the coming weeks, further validating its efficacy and safety profile.
D. Boral Capital Reiterates Buy Rating for Coya Therapeutics with $15 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.
Coya Therapeutics Reveals Pricing for Increased $20 Million Public Offering of Common Stock
Public Offering Announcement: Coya Therapeutics has priced an underwritten public offering of 3,636,364 shares of common stock at $5.50 per share, aiming to raise approximately $20 million for working capital and clinical development.
Underwriter and Closing Details: Lucid Capital Markets is the sole book-running manager for the offering, which is expected to close around October 27, 2025, pending customary closing conditions.
Company Overview: Coya Therapeutics, based in Houston, focuses on developing biologics to enhance regulatory T cell function for treating neurodegenerative disorders, with a pipeline that includes Treg-enhancing biologics and cell therapies.
Investigational Product COYA 302: COYA 302 is a proprietary biologic therapy aimed at treating ALS by enhancing Treg function and suppressing inflammation, currently being evaluated in a Phase 2 clinical trial.
Coya Therapeutics Declines Following $20M Stock Offering Announcement
Public Offering Details: Coya Therapeutics has announced a public offering of 3,636,364 shares priced at $5.50 each, aiming to raise approximately $20 million, with a potential additional 545,454 shares available to the underwriter.
Use of Proceeds: The company plans to utilize the net proceeds from the offering for working capital and general corporate purposes, including funding its clinical development plan.
Closing Timeline: The offering is expected to close around October 27, 2025, subject to standard closing conditions.
Market Reaction: Following the announcement, Coya Therapeutics' stock saw a premarket decline of 12.7%, trading at $6.09.
Coya Therapeutics Secures $11.1 Million in Private Placement
- Funding Size: Coya Therapeutics announced the sale of approximately 2.52 million shares at $4.40 per share, raising about $11.1 million, which will provide essential capital to accelerate the commercial readiness of its COYA 302 program.
- Investor Background: In this financing round, Dr. Reddy’s Laboratories invested $10 million through a subsidiary, while the company's largest institutional shareholder, Greenlight Capital, contributed $1.1 million, reflecting strong market confidence and support for Coya.
- Use of Proceeds: Coya plans to utilize the funds raised to expedite technology transfer and scale-up manufacturing for low-dose IL-2, thereby enhancing its competitive position in the market as it prepares for the commercialization of COYA 302.
- Transaction Timeline: The private placement is expected to close on or about January 30, 2026, subject to customary conditions, which ensures future liquidity and project advancement for the company.
Coya Therapeutics Secures $11.1 Million in Private Placement
- Funding Amount: Coya Therapeutics has secured approximately $11.1 million through a private placement of 2,522,727 shares at $4.40 each, reflecting strong market confidence in its biologics development.
- Key Investors: The primary investors include Dr. Reddy’s Laboratories, contributing $10 million, and Greenlight Capital with $1.1 million, indicating a positive outlook from institutional investors regarding Coya's future prospects.
- Use of Proceeds: The company intends to utilize the proceeds to accelerate technology transfer and scale-up manufacturing for low-dose IL-2, supporting the commercial readiness of COYA 302, thereby enhancing its competitive position in the neurodegenerative disease market.
- Compliance Commitment: Coya has committed to filing a registration statement with the SEC within 45 days post-closing, ensuring the legal resale of the securities, which will bolster investor confidence and facilitate future capital operations.
Coya Therapeutics Receives FDA IND Approval for COYA 302 to Treat Frontotemporal Dementia
- FDA Approval: Coya Therapeutics announced that its IND for COYA 302 to treat frontotemporal dementia has been accepted by the FDA, marking a significant advancement in the treatment of neurodegenerative diseases and aiming to address the urgent medical needs of approximately 60,000 patients.
- Clinical Need: Frontotemporal dementia is the most common form of dementia in individuals under 65, with an average onset age of 58 and a survival time of only 7.5 years, making Coya's new therapy potentially transformative in improving patient quality of life and slowing disease progression.
- Scientific Rationale: COYA 302 employs a dual immunomodulatory mechanism designed to enhance the anti-inflammatory function of regulatory T cells, which Coya believes will provide a new treatment option for frontotemporal dementia patients, filling a significant gap in the current market with no effective therapies available.
- Clinical Trial Plans: Coya expects to announce topline results from an open-label study evaluating low-dose IL-2 and CTLA4-Ig in patients with mild-to-moderate frontotemporal dementia in the coming weeks, further validating its efficacy and safety profile.
D. Boral Capital Reiterates Buy Rating for Coya Therapeutics with $15 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.
Coya Therapeutics Reveals Pricing for Increased $20 Million Public Offering of Common Stock
Public Offering Announcement: Coya Therapeutics has priced an underwritten public offering of 3,636,364 shares of common stock at $5.50 per share, aiming to raise approximately $20 million for working capital and clinical development.
Underwriter and Closing Details: Lucid Capital Markets is the sole book-running manager for the offering, which is expected to close around October 27, 2025, pending customary closing conditions.
Company Overview: Coya Therapeutics, based in Houston, focuses on developing biologics to enhance regulatory T cell function for treating neurodegenerative disorders, with a pipeline that includes Treg-enhancing biologics and cell therapies.
Investigational Product COYA 302: COYA 302 is a proprietary biologic therapy aimed at treating ALS by enhancing Treg function and suppressing inflammation, currently being evaluated in a Phase 2 clinical trial.
Coya Therapeutics Declines Following $20M Stock Offering Announcement
Public Offering Details: Coya Therapeutics has announced a public offering of 3,636,364 shares priced at $5.50 each, aiming to raise approximately $20 million, with a potential additional 545,454 shares available to the underwriter.
Use of Proceeds: The company plans to utilize the net proceeds from the offering for working capital and general corporate purposes, including funding its clinical development plan.
Closing Timeline: The offering is expected to close around October 27, 2025, subject to standard closing conditions.
Market Reaction: Following the announcement, Coya Therapeutics' stock saw a premarket decline of 12.7%, trading at $6.09.
